

**Heart Failure Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Class (ACE Inhibitors, Angiotensin 2 Receptor Blockers, Beta Blockers, Diuretics, Aldosterone Antagonists, Inotropes, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, and By Competition**

Market Report | 2023-11-07 | 190 pages | TechSci Research

**AVAILABLE LICENSES:**

- Single User License \$4900.00
- Multi-User License \$5900.00
- Custom Research License \$8900.00

**Report description:**

Global Heart Failure Therapeutics Market is anticipated to project impressive growth in the forecast period. Heart failure is a chronic medical condition characterized by the heart's inability to pump blood effectively, leading to symptoms such as fatigue, shortness of breath, and fluid retention. It is a significant global health concern and a leading cause of hospitalizations and healthcare costs.

Key Market Drivers

Aging Population

The global population is aging at an unprecedented rate, with a significant impact on healthcare systems and markets worldwide. One of the healthcare sectors experiencing substantial growth due to this demographic shift is the global heart failure therapeutics market. As individuals live longer, the incidence of heart failure, a condition associated with aging, has been on the rise.

The aging population trend is a global phenomenon. It is the result of increased life expectancies, decreased birth rates, and advancements in healthcare that have significantly improved overall longevity. According to the United Nations, the world's elderly population is projected to nearly double by 2050, with individuals aged 60 and above expected to make up over 21% of the global population.

Heart failure is primarily a disease of the elderly. As people age, the risk of developing heart failure increases. The heart undergoes natural wear and tear over time, making it less efficient at pumping blood. Additionally, age-related factors like the

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

accumulation of plaque in the arteries, reduced elasticity of blood vessels, and changes in heart muscle contribute to the development of heart failure.

With more elderly individuals, there is a higher prevalence of heart failure cases. This translates to a larger patient pool in need of treatment, thereby driving demand for heart failure therapeutics. The elderly population often presents complex healthcare needs, including comorbidities such as diabetes, hypertension, and renal dysfunction. These factors necessitate a more comprehensive and multi-faceted approach to heart failure treatment, leading to increased utilization of heart failure therapeutics. Older adults are more likely to develop heart failure in its advanced stages. This often requires more intensive management and the use of a broader range of therapeutics, including pharmaceuticals, medical devices, and surgical interventions. The economic burden of heart failure on healthcare systems is substantial. The cost of hospitalizations, medications, and long-term care for elderly heart failure patients contributes significantly to the growth of the heart failure therapeutics market.

Recognizing the growing demand for heart failure therapeutics due to the aging population, pharmaceutical companies have invested heavily in research and development. New drug classes and therapies have emerged, offering improved treatment options that cater to the specific needs of elderly patients.

#### Rising Incidence of Chronic Diseases

The global healthcare landscape is witnessing a dramatic increase in the prevalence of chronic diseases. This alarming trend has significant implications for various medical sectors, including the global heart failure therapeutics market. As chronic conditions like diabetes, hypertension, and obesity become more prevalent worldwide, the incidence of heart failure, a serious and life-threatening consequence of these diseases, is also on the rise.

Chronic diseases, often referred to as non-communicable diseases (NCDs), are characterized by their prolonged duration and slow progression. These diseases include diabetes, hypertension, obesity, coronary artery disease, and chronic kidney disease, among others. They are often associated with lifestyle factors such as poor diet, lack of physical activity, and tobacco use.

One of the critical consequences of untreated or poorly managed chronic diseases is heart failure. Chronic diseases can damage the heart muscle, impair blood flow, and increase the risk of heart failure development. For example, uncontrolled hypertension can lead to heart muscle thickening and impaired relaxation, while diabetes can damage blood vessels and nerves, affecting the heart's ability to pump efficiently.

As more individuals are diagnosed with chronic diseases, there is a larger patient pool at risk of developing heart failure. This expanded population contributes to the growing demand for heart failure therapeutics. Patients with multiple chronic conditions often require comprehensive and tailored treatment approaches. Heart failure management in the context of these comorbidities necessitates a combination of therapeutics, including medications, medical devices, and lifestyle modifications. Chronic diseases, when left unmanaged, can lead to hospitalizations, emergency room visits, and increased healthcare costs. Preventing and effectively treating heart failure in these patients can help mitigate the economic burden on healthcare systems, driving investment in therapeutics. The pharmaceutical industry recognizes the link between chronic diseases and heart failure. To address this, pharmaceutical companies are investing in research and development to create specialized drugs and therapies targeting heart failure in patients with underlying chronic conditions. The rising incidence of chronic diseases has prompted greater emphasis on preventive healthcare measures. Early diagnosis, lifestyle interventions, and the use of therapeutics to prevent heart failure are becoming more prevalent, leading to increased utilization of related treatments.

#### Pharmaceutical Innovation

In recent years, pharmaceutical innovation has played a pivotal role in advancing medical treatments across various therapeutic areas. Among these, the field of cardiology has seen remarkable progress in the development of heart failure therapeutics. With a growing global burden of heart failure, characterized by the heart's inability to pump blood effectively, pharmaceutical innovation has emerged as a driving force behind the growth of the global heart failure therapeutics market.

Heart failure remains a significant global health concern, with millions of people affected worldwide. Contributing factors include an aging population, an increase in chronic diseases, and evolving lifestyles that may exacerbate heart health risks. Heart failure not only impacts patients' quality of life but also places a substantial economic burden on healthcare systems due to hospitalizations and long-term care.

Pharmaceutical companies have introduced innovative drug classes such as angiotensin receptor-neprilysin inhibitors (ARNIs) and

sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors). These medications offer improved outcomes for heart failure patients, reducing hospitalizations and enhancing overall quality of life. Advancements in pharmacogenomics and personalized medicine are allowing healthcare providers to tailor heart failure treatments to individual patients. Genetic and molecular profiling help identify specific drug therapies that are more likely to be effective, leading to better outcomes. Research in combination therapies has led to the development of treatment regimens that target multiple pathways contributing to heart failure. These approaches can improve therapeutic efficacy and reduce disease progression. Pharmaceutical innovation is not limited to medications. It also includes the development of implantable devices like cardiac resynchronization therapy (CRT) and left ventricular assist devices (LVADs), which can provide life-saving support for advanced heart failure patients. The pharmaceutical industry conducts extensive clinical trials to test the safety and efficacy of new heart failure therapeutics. These trials expand the knowledge base, validate treatment approaches, and pave the way for regulatory approvals. Collaboration between pharmaceutical companies, academic institutions, and healthcare providers is driving research forward. These partnerships promote knowledge sharing, accelerate drug development, and ensure that patients have access to the latest innovations.

#### Healthcare Infrastructure Development

The global healthcare landscape is constantly evolving, with significant efforts being made to enhance healthcare infrastructure and services worldwide. One critical area where these advancements have a profound impact is the global heart failure therapeutics market. The development of healthcare infrastructure plays a pivotal role in driving growth within this sector. Heart failure is a chronic condition characterized by the heart's inability to effectively pump blood, leading to a range of debilitating symptoms and increased risk of hospitalization. It is a major public health concern, affecting millions of individuals worldwide, and is associated with substantial healthcare costs.

Healthcare infrastructure encompasses hospitals, clinics, medical personnel, and resources necessary to deliver healthcare services effectively. The development and improvement of healthcare infrastructure have several direct and indirect impacts on the growth of the heart failure therapeutics market:

Investments in healthcare infrastructure expand the geographic reach of healthcare services, ensuring that heart failure patients have access to specialized care, diagnostics, and treatments. This increased access can lead to earlier diagnosis and intervention. Improved healthcare facilities equipped with advanced diagnostic tools enable healthcare providers to diagnose heart failure more accurately and at earlier stages. Timely diagnosis allows for prompt initiation of heart failure therapeutics, improving patient outcomes. Developed healthcare infrastructure ensures a reliable supply chain for medications, including heart failure therapeutics. Patients can access essential medications without interruptions, contributing to adherence and treatment efficacy. Healthcare infrastructure development often involves the establishment of specialized heart failure centers or units within healthcare facilities. These centers focus on providing comprehensive care and expertise in heart failure management. Rehabilitation programs for heart failure patients are crucial for improving their quality of life. Healthcare infrastructure development facilitates the availability of cardiac rehabilitation services, promoting patient recovery and long-term well-being. Infrastructure development can include the acquisition of state-of-the-art cardiac technologies and the training of healthcare professionals in advanced procedures. This can lead to more effective interventions, including cardiac surgeries and implantation of heart-assist devices.

#### Key Market Challenges

##### Rising Healthcare Costs

One of the most significant challenges in heart failure therapeutics is the increasing cost of healthcare. The development, production, and distribution of heart failure medications and treatments are expensive processes. This results in higher prices for patients, which can be a barrier to access for those with limited financial means.

##### Drug Development Costs

The process of developing new heart failure therapeutics is costly and time-consuming. Clinical trials, research, and regulatory compliance demand substantial investments, and not all potential treatments make it to market. The high cost of drug development can deter pharmaceutical companies from pursuing innovative therapies.

##### Drug Pricing and Reimbursement

Setting prices for heart failure therapeutics is a complex issue. Manufacturers must strike a balance between recouping their development costs and ensuring access to treatments. Negotiations with insurers and government agencies for reimbursement

can further complicate pricing and market access.

#### Key Market Trends

##### Novel Drug Classes

Pharmaceutical innovation is bringing forth novel drug classes specifically designed to address heart failure. These include angiotensin receptor-neprilysin inhibitors (ARNIs) and sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors). These medications offer improved efficacy, reducing hospitalizations and enhancing patients' quality of life.

##### Cardiac Implantable Devices

Implantable devices such as cardiac resynchronization therapy (CRT) devices and left ventricular assist devices (LVADs) are becoming more sophisticated and accessible. They provide essential support for patients with advanced heart failure, extending life and improving quality of life.

##### Biomarkers for Early Detection

Research is underway to identify specific biomarkers that can predict the onset of heart failure before symptoms manifest. Early detection enables interventions to prevent disease progression, offering hope for improved outcomes.

#### Segmental Insights

##### Drug Class Insights

Based on the category of Drug Class, the ACE inhibitors category emerged as the dominant force within the market in 2022. This can be attributed to its efficacy as a standalone treatment or its approved combinations available in the market. Additionally, it holds the top position as the preferred treatment option for patients suffering from congestive heart failure (CHF). This category encompasses medications such as Vasotec, Epaned (enalapril), Zestril, Qbrelis, Prinivil (lisinopril), and captopril. These inhibitors function by blocking the production of Angiotensin-2, reducing arterial pressure, thereby leading to an increased cardiac output, all without impacting heart rate. This represents the most precisely targeted mechanism of action for managing heart failure. Moreover, the expected approval of expanded labels for sodium-glucose co-transporter 2 (SGLT2) inhibitors specifically for CHF is anticipated to drive growth in this segment. For instance, in May 2020, Farxiga (dapagliflozin), and in February 2022, Jardiance (empagliflozin), received label extensions for the treatment of CHF. These SGLT2 inhibitor drugs have clinically demonstrated significant benefits in protecting the heart and have shown a remarkable 35% reduction in hospitalization rates. Notably, this drug class has also proven its clinical significance in managing CHF in patients who do not have diabetes.

##### Distribution Channel Insights

In 2022, hospital pharmacies claimed the largest market share. However, it is anticipated that the retail pharmacies segment will experience the most substantial growth in the foreseeable future. Retail pharmacies are well-suited for a wide range of medications, particularly in the context of homecare, given that the management of CHF often requires extended medication support. Moreover, CHF drugs are typically prescription medications, further bolstering the prospects of this segment. Concurrently, the online pharmacies sector is projected to expand at a noteworthy CAGR in the forecast period. Online pharmacy platforms offer the convenience of purchasing medications. Additionally, in emerging economies like India, companies such as Netmeds Marketplace Ltd. and Tata 1mg are actively promoting the online procurement of medicines. Nevertheless, the online purchase of prescription drugs faces resistance from some individuals, which is expected to dampen the growth of the online pharmacy segment.

##### Regional Insights

In 2022, North America commanded the largest market share, and this can be attributed to several factors including a high disease burden, increased patient awareness, a rise in healthcare expenditure, and the presence of major industry players in the region. Additionally, the industry is expected to experience further growth in the forecast period, driven by the increasing approval of new products.

In Europe, Italy had the lowest impact, while Germany exhibited the highest prevalence of CHF in 2021. Meanwhile, the Asia Pacific region is projected to register the highest CAGR during the forecast period. This growth is primarily driven by the significant presence of global companies in the region and the elevated prevalence of CHF in countries like China, Japan, and Australia. For example, in 2020, Australia reported estimated CHF prevalence rates ranging from 1.2% to 5.3%, largely attributed to the increasing incidences of diabetes and obesity in the country.

#### Key Market Players

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Bayer AG  
Novartis AG  
Merck & Co., Inc.  
AstraZeneca PLC  
Bristol-Myers Squibb Co  
Amgen Inc  
Boehringer Ingelheim GmbH  
Pfizer Inc  
Johnson & Johnson  
Eli Lilly and Company

**Report Scope:**

In this report, the Global Heart Failure Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

**Heart Failure Therapeutics Market, By Drug Class:**

- o ACE Inhibitors
- o Angiotensin 2 Receptor Blockers
- o Beta Blockers
- o Diuretics
- o Aldosterone Antagonists
- o Inotropes
- o Others

**Heart Failure Therapeutics Market, By Distribution Channel:**

- o Hospital Pharmacies
- o Retail Pharmacies
- o Online Pharmacies

**Heart Failure Therapeutics Market, By Region:**

- o North America
  - ? United States
  - ? Canada
  - ? Mexico
- o Europe
  - ? Germany
  - ? United Kingdom
  - ? France
  - ? Italy
  - ? Spain
- o Asia-Pacific
  - ? China
  - ? Japan
  - ? India
  - ? Australia
  - ? South Korea
- o South America
  - ? Brazil
  - ? Argentina
  - ? Colombia
- o Middle East & Africa

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

? South Africa

? Saudi Arabia

? UAE

? Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Heart Failure Therapeutics Market.

Available Customizations:

Global Heart Failure Therapeutics market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

? Detailed analysis and profiling of additional market players (up to five).

## **Table of Contents:**

### 1. Product Overview

#### 1.1. Market Definition

#### 1.2. Scope of the Market

##### 1.2.1. Markets Covered

##### 1.2.2. Years Considered for Study

##### 1.2.3. Key Market Segmentations

### 2. Research Methodology

#### 2.1. Objective of the Study

#### 2.2. Baseline Methodology

#### 2.3. Key Industry Partners

#### 2.4. Major Association and Secondary Sources

#### 2.5. Forecasting Methodology

#### 2.6. Data Triangulation & Validation

#### 2.7. Assumptions and Limitations

### 3. Executive Summary

#### 3.1. Overview of the Market

#### 3.2. Overview of Key Market Segmentations

#### 3.3. Overview of Key Market Players

#### 3.4. Overview of Key Regions/Countries

#### 3.5. Overview of Market Drivers, Challenges, Trends

### 4. Voice of Customer

### 5. Global Heart Failure Therapeutics Market Outlook

#### 5.1. Market Size & Forecast

##### 5.1.1. By Value

#### 5.2. Market Share & Forecast

##### 5.2.1. By Drug Class (ACE Inhibitors, Angiotensin 2 Receptor Blockers, Beta Blockers, Diuretics, Aldosterone Antagonists, Inotropes, Others)

##### 5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

##### 5.2.3. By Region

##### 5.2.4. By Company (2022)

#### 5.3. Product Market Map

##### 5.3.1. By Drug Class

##### 5.3.2. By Distribution Channel

##### 5.3.3. By Region

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6. North America Heart Failure Therapeutics Market Outlook
  - 6.1. Market Size & Forecast
    - 6.1.1. By Value
  - 6.2. Market Share & Forecast
    - 6.2.1. By Drug Class (ACE Inhibitors, Angiotensin 2 Receptor Blockers, Beta Blockers, Diuretics, Aldosterone Antagonists, Inotropes, Others)
    - 6.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    - 6.2.3. By Country
  - 6.3. North America: Country Analysis
    - 6.3.1. United States Heart Failure Therapeutics Market Outlook
      - 6.3.1.1. Market Size & Forecast
        - 6.3.1.1.1. By Value
      - 6.3.1.2. Market Share & Forecast
        - 6.3.1.2.1. By Drug Class
        - 6.3.1.2.2. By Distribution Channel
    - 6.3.2. Canada Heart Failure Therapeutics Market Outlook
      - 6.3.2.1. Market Size & Forecast
        - 6.3.2.1.1. By Value
      - 6.3.2.2. Market Share & Forecast
        - 6.3.2.2.1. By Drug Class
        - 6.3.2.2.2. By Distribution Channel
    - 6.3.3. Mexico Heart Failure Therapeutics Market Outlook
      - 6.3.3.1. Market Size & Forecast
        - 6.3.3.1.1. By Value
      - 6.3.3.2. Market Share & Forecast
        - 6.3.3.2.1. By Drug Class
        - 6.3.3.2.2. By Distribution Channel
- 7. Europe Heart Failure Therapeutics Market Outlook
  - 7.1. Market Size & Forecast
    - 7.1.1. By Value
  - 7.2. Market Share & Forecast
    - 7.2.1. By Drug Class (ACE Inhibitors, Angiotensin 2 Receptor Blockers, Beta Blockers, Diuretics, Aldosterone Antagonists, Inotropes, Others)
    - 7.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    - 7.2.3. By Country
  - 7.3. Europe: Country Analysis
    - 7.3.1. Germany Heart Failure Therapeutics Market Outlook
      - 7.3.1.1. Market Size & Forecast
        - 7.3.1.1.1. By Value
      - 7.3.1.2. Market Share & Forecast
        - 7.3.1.2.1. By Drug Class
        - 7.3.1.2.2. By Distribution Channel
    - 7.3.2. United Kingdom Heart Failure Therapeutics Market Outlook
      - 7.3.2.1. Market Size & Forecast
        - 7.3.2.1.1. By Value
      - 7.3.2.2. Market Share & Forecast
        - 7.3.2.2.1. By Drug Class

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 7.3.2.2.2. By Distribution Channel
- 7.3.3. France Heart Failure Therapeutics Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Drug Class
    - 7.3.3.2.2. By Distribution Channel
- 7.3.4. Italy Heart Failure Therapeutics Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Drug Class
    - 7.3.4.2.2. By Distribution Channel
- 7.3.5. Spain Heart Failure Therapeutics Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Drug Class
    - 7.3.5.2.2. By Distribution Channel
- 8. Asia-Pacific Heart Failure Therapeutics Market Outlook
  - 8.1. Market Size & Forecast
    - 8.1.1. By Value
  - 8.2. Market Share & Forecast
    - 8.2.1. By Drug Class (ACE Inhibitors, Angiotensin 2 Receptor Blockers, Beta Blockers, Diuretics, Aldosterone Antagonists, Inotropes, Others)
    - 8.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    - 8.2.3. By Country
  - 8.3. Asia-Pacific: Country Analysis
    - 8.3.1. China Heart Failure Therapeutics Market Outlook
      - 8.3.1.1. Market Size & Forecast
        - 8.3.1.1.1. By Value
      - 8.3.1.2. Market Share & Forecast
        - 8.3.1.2.1. By Drug Class
        - 8.3.1.2.2. By Distribution Channel
    - 8.3.2. Japan Heart Failure Therapeutics Market Outlook
      - 8.3.2.1. Market Size & Forecast
        - 8.3.2.1.1. By Value
      - 8.3.2.2. Market Share & Forecast
        - 8.3.2.2.1. By Drug Class
        - 8.3.2.2.2. By Distribution Channel
    - 8.3.3. India Heart Failure Therapeutics Market Outlook
      - 8.3.3.1. Market Size & Forecast
        - 8.3.3.1.1. By Value
      - 8.3.3.2. Market Share & Forecast
        - 8.3.3.2.1. By Drug Class
        - 8.3.3.2.2. By Distribution Channel
    - 8.3.4. Australia Heart Failure Therapeutics Market Outlook

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)



- 8.3.4.1.□Market Size & Forecast
  - 8.3.4.1.1.□By Value
- 8.3.4.2.□Market Share & Forecast
  - 8.3.4.2.1.□By Drug Class
  - 8.3.4.2.2.□By Distribution Channel
- 8.3.5.□South Korea Heart Failure Therapeutics Market Outlook
  - 8.3.5.1.□Market Size & Forecast
    - 8.3.5.1.1.□By Value
  - 8.3.5.2.□Market Share & Forecast
    - 8.3.5.2.1.□By Drug Class
    - 8.3.5.2.2.□By Distribution Channel
- 9.□South America Heart Failure Therapeutics Market Outlook
  - 9.1.□Market Size & Forecast□
    - 9.1.1.□By Value
  - 9.2.□Market Share & Forecast
    - 9.2.1.□By Drug Class (ACE Inhibitors, Angiotensin 2 Receptor Blockers, Beta Blockers, Diuretics, Aldosterone Antagonists, Inotropes, Others)
    - 9.2.2.□By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    - 9.2.3.□By Country
  - 9.3.□South America: Country Analysis
    - 9.3.1.□Brazil Heart Failure Therapeutics Market Outlook
      - 9.3.1.1.□Market Size & Forecast
        - 9.3.1.1.1.□By Value
      - 9.3.1.2.□Market Share & Forecast
        - 9.3.1.2.1.□By Drug Class
        - 9.3.1.2.2.□By Distribution Channel
    - 9.3.2.□Argentina Heart Failure Therapeutics Market Outlook
      - 9.3.2.1.□Market Size & Forecast
        - 9.3.2.1.1.□By Value
      - 9.3.2.2.□Market Share & Forecast
        - 9.3.2.2.1.□By Drug Class
        - 9.3.2.2.2.□By Distribution Channel
    - 9.3.3.□Colombia Heart Failure Therapeutics Market Outlook
      - 9.3.3.1.□Market Size & Forecast
        - 9.3.3.1.1.□By Value
      - 9.3.3.2.□Market Share & Forecast
        - 9.3.3.2.1.□By Drug Class
        - 9.3.3.2.2.□By Distribution Channel
- 10.□Middle East and Africa Heart Failure Therapeutics Market Outlook
  - 10.1.□Market Size & Forecast□
    - 10.1.1.□By Value
  - 10.2.□Market Share & Forecast
    - 10.2.1.□By Drug Class (ACE Inhibitors, Angiotensin 2 Receptor Blockers, Beta Blockers, Diuretics, Aldosterone Antagonists, Inotropes, Others)
    - 10.2.2.□By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    - 10.2.3.□By Country
  - 10.3.□MEA: Country Analysis

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.3.1. South Africa Heart Failure Therapeutics Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Drug Class
    - 10.3.1.2.2. By Distribution Channel
- 10.3.2. Saudi Arabia Heart Failure Therapeutics Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Drug Class
    - 10.3.2.2.2. By Distribution Channel
- 10.3.3. UAE Heart Failure Therapeutics Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Drug Class
    - 10.3.3.2.2. By Distribution Channel
- 10.3.4. Kuwait Heart Failure Therapeutics Market Outlook
  - 10.3.4.1. Market Size & Forecast
    - 10.3.4.1.1. By Value
  - 10.3.4.2. Market Share & Forecast
    - 10.3.4.2.1. By Drug Class
    - 10.3.4.2.2. By Distribution Channel
- 11. Market Dynamics
  - 11.1. Drivers
  - 11.2. Challenges
- 12. Market Trends & Developments
  - 12.1. Recent Development
  - 12.2. Mergers & Acquisitions
  - 12.3. Product Launches
- 13. Porter's Five Forces Analysis
  - 13.1. Competition in the Industry
  - 13.2. Potential of New Entrants
  - 13.3. Power of Suppliers
  - 13.4. Power of Customers
  - 13.5. Threat of Substitute Products
- 14. Competitive Landscape
  - 14.1. Business Overview
  - 14.2. Product Offerings
  - 14.3. Recent Developments
  - 14.4. Financials (As Reported)
  - 14.5. Key Personnel
  - 14.6. SWOT Analysis
    - 14.6.1. Bayer AG
    - 14.6.2. Novartis AG
    - 14.6.3. Merck & Co., Inc.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 14.6.4. AstraZeneca PLC
- 14.6.5. Bristol-Myers Squibb Co
- 14.6.6. Amgen Inc
- 14.6.7. Boehringer Ingelheim GmbH
- 14.6.8. Pfizer Inc
- 14.6.9. Johnson & Johnson
- 14.6.10. Eli Lilly and Company
- 15. Strategic Recommendations
- 16. About Us & Disclaimer

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Heart Failure Therapeutics Market - Global Industry Size, Share, Trends,  
Opportunity, and Forecast, 2018-2028 Segmented By Drug Class (ACE Inhibitors,  
Angiotensin 2 Receptor Blockers, Beta Blockers, Diuretics, Aldosterone Antagonists,  
Inotropes, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies,  
Online Pharmacies), By Region, and By Competition**

Market Report | 2023-11-07 | 190 pages | TechSci Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$4900.00
	Multi-User License	\$5900.00
	Custom Research License	\$8900.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-01"/>
		Signature	<input type="text"/>